Refine by
Neck Cancers Articles & Analysis: Older
39 news found
CD BioSciences now offers a comprehensive portfolio of Nervous System Tissue Microarrays, including Brain Tissue Microarrays and Head & Neck Tissue Microarrays. This comprehensive offering provides researchers with a powerful tool for studying various neurological disorders, including brain tumors, head and neck cancers, and neurodegenerative ...
(TSX-V: PINK)(OTC: PYNKF) (FSE: 4PC) (“Perimeter” or the “Company”) announced the publication of a peer-reviewed research article in JAMA Otolaryngology—Head and Neck Surgery. The study’s findings validate the further exploration of the use of Perimeter’s wide-field Optical Coherence Tomography (WF-OCT) technology to visualize margins ...
Neutron Therapeutics is now in a position to maximize the potential of BNCT and to begin delivering its benefits to cancer patients," saidDr. Elizabeth Reczek, CEO of Neutron Therapeutics. ...
If you are one of those individuals waking up multiple times throughout the night, your affliction can be treated with help from a dental practitioner, oftentimes in tandem with a nasal surgery. Oral Cancer Oral cancer is the most prevalent form of head and neck cancer. ...
Celularity reported its findings in a poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting held in Washington, D.C., November 10-14, 2021. Poster 159: Developing placental CD34+-derived natural killer cells with high affinity cleavage resistant CD16 (CYNK-101) and Cetuximab for enhanced therapy of EGFR+ non-small cell lung and head and ...
’s (NYSE American: ISR) Cesium-131 in treating prostate cancer was highlighted in two presentations at the just concluded American Brachytherapy Society’s annual conference in Denver, Colorado. ...
Fifty-four patients had advanced HPV16+ head and neck cancers with a median of three prior therapies (range of 1-11), including a checkpoint inhibitor regimen in 50 of the 54. ...
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that an abstract reporting preliminary data from the two Phase I trials assessing TG4050, its individualized neoantigen cancer vaccine, has been selected for a poster presentation at the American Society of Clinical ...
– 5:45 p.m. CDT during the Head and Neck Cancer session. Topline data was announced in December 2021. Abstracts are currently available in the ASCO digital program. ...
Phase 1 data show single-vector HB-201 and 2-vector HB-202/HB-201 were generally well tolerated, rapidly induced tumor-specific T cells and showed anti-tumor activity in heavily pre-treated head and neck cancer patients Poster presentation to include data supporting recommended Phase 2 dose for alternating 2-vector HB-202/HB-201 and Phase 2 development plans ...
About Severe Oral Mucositis (SOM) Approximately 42,000 patients with head and neck cancer undergo standard-of-care radiotherapy every year in the U.S. and are at risk of experiencing SOM. In patients with head and neck cancer, radiotherapy is a mainstay of treatment. Approximately 70 percent of patients receiving radiotherapy for ...
Johanna Mattson, Senior Medical Director at the Helsinki University Hospital Comprehensive Cancer Center, commented: "Providing BNCT with the most sophisticated accelerator-based device will enable Finnish clinicians to treat patients with some of the most obstinate cancers and remain globally at the forefront of oncology. ...
No Grade 4 or 5 esophagitis in patients treated with avasopasem Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced topline results from the six-week, Phase 2a, open-label, single-arm AESOP trial of ...
Oral Presentation Title: ROMAN: Phase 3 trial of avasopasem manganese (GC4419) for severe oral mucositis (SOM) in patients receiving chemoradiotherapy (CRT) for locally advanced, nonmetastatic head and neck cancer (LAHNC) Abstract Number: 6005 Presenter: Carryn M. Anderson, M.D., University of Iowa Hospitals & Clinics Session Title: Head and ...
The data were shared as poster presentations at the 2022 American Association for Cancer Research Annual Meeting (AACR). “Our HB-200 clinical program biomarker data have confirmed our preclinical findings in head and neck cancers, so we’re encouraged by the preclinical findings presented at AACR as further evidence of the potential ...
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will present additional positive immunogenicity and clinical data on TG4050, its individualized neoantigen cancer vaccine. TG4050 is currently being evaluated in two ongoing multicenter Phase I trials in patients with ovarian ...
In October of last year, the medical and research teams were the first in the world to use the device when they inserted a feeding tube into a 76-year-old Sarnia man who was being treated with radiation therapy for head and neck cancer. “I had several weeks of radiation which killed my taste buds. ...
ByCoapTech
“I am excited to present our initial findings from this important collaboration with my colleagues at Washington University School of Medicine and GeneCentric evaluating molecular subtypes for head and neck cancer,” said Neil Hayes, MD, MPH, GeneCentric co-founder and Director of the University of Tennessee Health Science Center’s Center for ...
Curasight A / S ("Curasight" or "The Company") announces today that it is expanding and accelerating its clinical programs with two additional cancer indications - Neuroendocrine tumors (NET) and head and neck cancer. ...
Eligible tumor types include advanced non-small cell lung cancer, colorectal cancer, head and neck cancer, gastric cancer, breast cancer, ovarian cancer, and pancreatic cancer. ...